Navigation Links
Katherine Baicker Elected to Lilly Board of Directors
Date:12/12/2011

INDIANAPOLIS, Dec. 12, 2011 /PRNewswire/ -- Board of Directors of Eli Lilly and Company (NYSE: LLY) has elected Katherine Baicker, Ph.D. as a new member, effective December 12, 2011. Baicker, 40, is Professor of Health Economics in the Department of Health Policy and Management at the Harvard School of Public Health. She is also a research associate at the National Bureau of Economic Research and an elected member of the Institute of Medicine. As a member of Lilly's board, Professor Baicker will serve on the public policy and compliance committee. She will serve under interim election and will stand for election by Lilly shareholders at the company's annual meeting in April, 2012.

"I am very pleased to welcome Kate Baicker to the Lilly board. Her experience and expertise will surely benefit Lilly shareholders and the patients we serve," commented John Lechleiter, Ph.D., Lilly chairman, president and chief executive officer. "Kate is a leading researcher in the fields of health economics, public economics and labor economics. As a valued advisor to numerous healthcare-related commissions and committees, her expertise in healthcare policy and healthcare delivery is recognized by both academia and government. In a rapidly-changing healthcare landscape, Kate's insights will be invaluable as we work to sustain an environment that is conducive to medical innovation while still ensuring access to affordable, quality healthcare."

Professor Baicker's research focuses primarily on the factors that drive the distribution, generosity, and effectiveness of public and private health insurance, with a particular focus on health insurance finance and the effect of reforms on the distribution and quality of care.  Her research has been published in journals such as Health Affairs, the Journal of Public Economics, and the Quarterly Journal of Economics, and has been featured in the New York Times, the Wall Street Journal, Business Week, and on National Public Radio.  She is currently one of the leaders of a research program investigating the many effects of expanding health insurance coverage in the context of a randomized Medicaid expansion in Oregon.

Prior to her current position at the Harvard School of Public Health, Professor Baicker served as a Senate-confirmed Member of the President's Council of Economic Advisers from 2005 - 2007, where she played a leading role in the development of health policy.  She currently serves on the Editorial Boards of Health Affairs, the Journal of Health Economics, and the Forum for Health Economics and Policy; as Vice Chair of the Board of Directors of AcademyHealth; on the Congressional Budget Office's Panel of Health Advisers; and as a Commissioner on the Medicare Payment Advisory Commission.

About Lilly  
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
5. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
6. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
7. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
8. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
Breaking Medicine Technology:
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
Breaking Medicine News(10 mins):